We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+37.76%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.9B
AUM Growth
+$644M
(+15%)
Cap. Flow
-$263M
Cap. Flow
% of AUM
-5.37%
Top 10 Holdings %
Top 10 Hldgs %
40.38%
Holding
132
New
23
Increased
22
Reduced
35
Closed
25
Avg Time Held Equity + Options
8.6
quarters
Top 10 Avg Time Held Equity + Options
7
quarters
Top 20 Avg Time Held Equity + Options
8.2
quarters
Avg Time Held Equity only
8.7
quarters
Top 10 Avg Time Held Equity only
7
quarters
Top 20 Avg Time Held Equity only
8.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$41.7M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$37.3M |
| 3 |
Elevance Health
ELV
|
+$33.5M |
| 4 |
HELP
Helus Pharma Inc. Common Stock
HELP
|
+$24.7M |
| 5 |
Bruker
BRKR
|
+$23.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Terns Pharmaceuticals
TERN
|
+$125M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$65.8M |
| 3 |
Exact Sciences
EXAS
|
+$51.6M |
| 4 |
Axsome Therapeutics
AXSM
|
+$38.9M |
| 5 |
SI-BONE Inc
SIBN
|
+$38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.3% |
| 2 | Miscellaneous | 0.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Protagonist Therapeutics
PTGX
$8.99B
| $1.9M | 0.04% |
+21,700
| New | +$1.78M |
2025 Q4
0 quarters
|
|
102
PTC Therapeutics
PTCT
$5.01B
| $1.76M | 0.04% |
+23,200
| New | +$1.69M |
2025 Q4
0 quarters
|
|
103
MapLight Therapeutics
MPLT
$442M
| $952K | 0.02% |
+56,000
| New | +$938K |
2025 Q4
0 quarters
|
|
104
Traws Pharma
TRAW
$6.38M
| $684K | 0.01% |
605,531
| – | – |
2024 Q2
6 quarters
|
|
105
CALL
VistaGen Therapeutics
VTGN
$9.48M
| $29.9K | ﹤0.01% |
45,200
| – | – |
2025 Q3
1 quarter
|
|
106
CALL
Abbott
ABT
$178B
| – | – |
-150,000
| Closed | -$20.1M | – |
|
107
DELISTED
Akero Therapeutics
AKRO
| – | – |
-526,200
| Closed | -$25M | – |
|
108
Amylyx Pharmaceuticals
AMLX
$3.41B
| – | – |
-750,600
| Closed | -$10.2M | – |
|
109
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-250,000
| Closed | -$5.66M | – |
|
110
DELISTED
AtaiBeckley Inc
ATAI
| – | – |
-347,000
| Closed | -$1.84M | – |
|
111
CALL
AstraZeneca
AZN
$243B
| – | – |
-75,000
| Closed | -$11.5M | – |
|
112
CALL
Boston Scientific
BSX
$63.1B
| – | – |
-200,000
| Closed | -$19.5M | – |
|
113
PUT
DELISTED
Crinetics Pharmaceuticals
CRNX
| – | – |
-100,000
| Closed | -$4.17M | – |
|
114
Immatics
IMTX
$1.07B
| – | – |
-466,601
| Closed | -$3.98M | – |
|
115
Integer Holdings
ITGR
$4.31B
| – | – |
-290,000
| Closed | -$30M | – |
|
116
Korro Bio
KRRO
$127M
| – | – |
-32,400
| Closed | -$1.55M | – |
|
117
DELISTED
Kezar Life Sciences
KZR
| – | – |
-192,700
| Closed | -$752K | – |
|
118
Lyell Immunopharma
LYEL
$185M
| – | – |
-51,727
| Closed | -$840K | – |
|
119
Milestone Pharmaceuticals
MIST
$97.6M
| – | – |
-3,221,828
| Closed | -$6.44M | – |
|
120
DELISTED
Mural Oncology
MURA
| – | – |
-588,800
| Closed | -$1.22M | – |
|
121
Passage Bio
PASG
$12.7M
| – | – |
-59,046
| Closed | -$474K | – |
|
|
122
CALL
Pfizer
PFE
$161B
| – | – |
-500,000
| Closed | -$12.7M | – |
|
123
DELISTED
scPharmaceuticals
SCPH
| – | – |
-6,059,528
| Closed | -$34.4M | – |
|
|
124
SI-BONE Inc
SIBN
$899M
| – | – |
-2,578,979
| Closed | -$38M | – |
|
125
CALL
Scholar Rock
SRRK
$5B
| – | – |
-100,000
| Closed | -$3.72M | – |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q4 2025 Portfolio in Review
As of Q4 2025, OrbiMed held 132 positions worth $4.9B, up 15% from $4.26B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
OrbiMed withdrew a net $263M in Q4 2025, closing 25 positions and reducing 35 holdings. Its most notable exit was SI-BONE Inc, an estimated $38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Pfizer worth $41.2M.
- OrbiMed's largest Q4 2025 buy was Pfizer: 1,652,900 shares worth $41.2M.
- OrbiMed added most to RAPT Therapeutics in Q4 2025, an estimated $17.3M increase.
- OrbiMed's biggest Q4 2025 reduction was Terns Pharmaceuticals, cutting an estimated $125M.
- OrbiMed fully exited SI-BONE Inc in Q4 2025, selling an estimated $38M.
- OrbiMed's ten largest holdings make up 40% of its $4.9B portfolio in Q4 2025.
- OrbiMed opened 23 new positions and closed 25 in Q4 2025.
- OrbiMed's portfolio value rose 15% quarter-over-quarter to $4.9B.
Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.